NCT00656435View on ClinicalTrials.gov

Bevacizumab and Long Acting Gas in Diabetic Vitrectomy

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

February 29, 2008

Conditions
Proliferative Diabetic Retinopathy
Interventions
DRUG

Bevacizumab

Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy

Trial Locations (1)

100

Department of Ophthalmology, National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT00656435 - Bevacizumab and Long Acting Gas in Diabetic Vitrectomy | Biotech Hunter | Biotech Hunter